Edge Rewrite
restyle Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

Jump to content

OML-632

Edit links
From Wikipedia, the free encyclopedia

OML-632
Clinical data
Other namesOML-632; OML632; 1-Hydroxymethyllysergic acid diethylamide; 1-Hydroxymethyl-d-lysergic acid diethylamide; 1-Oxy-methyl-LSD; 1-Oxymethyl-LSD; Oxymethyl-LSD
Routes of
administration		Oral
Drug classSerotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • (6aR,9R)-N,N-Diethyl-4-(hydroxymethyl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
CAS Number
Chemical and physical data
FormulaC21H27N3O2
Molar mass353.466 g·mol−1
3D model (JSmol)
  • CCN(C(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)cn3CO)CC
  • InChI=1S/C21H27N3O2/c1-4-23(5-2)21(26)15-9-17-16-7-6-8-18-20(16)14(12-24(18)13-25)10-19(17)22(3)11-15/h6-9,12,15,19,25H,4-5,10-11,13H2,1-3H3/t15-,19-/m1/s1
  • Key:MCNBQMJSTKRHKK-DNVCBOLYSA-N

OML-632, also known as 1-hydroxymethyllysergic acid diethylamide (1-hydroxymethyl-LSD), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2][3][4][5][6][7]

Interactions

[edit]

Pharmacology

[edit]

Pharmacodynamics

[edit]

OML-632 has about 66% of the hallucinogenic potency of LSD in humans (which is stated as active at 50–100 μg) and about 59% of the antiserotonergic activity of LSD in the isolated rat uterus in vitro.[8][9][5][6][10][11] However, OML-632 may simply act as a prodrug of LSD.[6][11] It has also been said to serve as a metabolic intermediate in the demethylation of 1-methyl-LSD (MLD-41) into LSD.[11]

History

[edit]

OML-632 was first described in the scientific literature by 1957.[12][13][4][14] The compound has been mistakenly referred to as "1-methoxy-LSD" or "1-MeO-LSD" in some publications.[15][16][17]

See also

[edit]

References

[edit]
  1. ↑ Shulgin AT (1982). "Chemistry of Psychotomimetics". In Hoffmeister F, Stille G (eds.). Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs. Handbook of Experimental Pharmacology. Vol. 55 / 3. Berlin: Springer Berlin Heidelberg. pp. 3–29. doi:10.1007/978-3-642-67770-0_1. ISBN 978-3-642-67772-4. OCLC 8130916.
  2. ↑ Shulgin AT (1976). "Psychotomimetic Agents". In Gordon M (ed.). Psychopharmacological Agents: Use, Misuse and Abuse. Medicinal Chemistry: A Series of Monographs. Vol. 4. Academic Press. pp. 59–146. doi:10.1016/b978-0-12-290559-9.50011-9. ISBN 978-0-12-290559-9.
  3. ↑ Shulgin AT (1980). "Hallucinogens". In Burger A, Wolf ME (eds.). Burger's Medicinal Chemistry. Vol. 3 (4 ed.). New York: Wiley. pp. 1109–1137. ISBN 978-0-471-01572-7. OCLC 219960627.
  4. 1 2 Abramson HA (1959). "Lysergic Acid Diethylamide (LSD-25): XXIX. The Response Index as a Measure of Threshold Activity of Psychotropic Drugs in Man". The Journal of Psychology. 48 (1): 65–78. doi:10.1080/00223980.1959.9916341. ISSN 0022-3980.
  5. 1 2 Fanchamps A (1978). "Some Compounds With Hallucinogenic Activity". In Berde B, Schild HO (eds.). Ergot Alkaloids and Related Compounds. Handbook of Experimental Pharmacology (HEP). Vol. 49. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 567–614. doi:10.1007/978-3-642-66775-6_8. ISBN 978-3-642-66777-0. Archived from the original on 30 March 2025. Table 2. Psychotomimetic activity and some pharmacodynamic effects of structural analogues of LSD [...]
  6. 1 2 3 Mangner TJ (1978). Potential Psychotomimetic Antagonists. N,N-diethyl-1-methyl-3-aryl-1,2,5,6-tetrahydropyridine-5-carboxamides (Ph.D. thesis). University of Michigan. doi:10.7302/11268. Archived from the original on 30 March 2025. 1-Hydroxymethyl LSD (25) was found to have about two-thirds the activity of LSD by Cerletti52 and Abramson,5,53 but since both 1-hydroxymethyl-LSD and 1-acetyl-LSD "are very easily hydrolyzed under alkaline conditions,"62 the high potency of these compounds might be a result of their in vivo hydrolysis to the active LSD. [...] Table 1. Human psychotomimetic potencies of LSD analogs. [...]
  7. ↑ Rutschmann J, Stadler PA (1978). "Chemical Background". Ergot Alkaloids and Related Compounds. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 29–85. doi:10.1007/978-3-642-66775-6_2. ISBN 978-3-642-66777-0.
  8. ↑ Abramson HA (1968). "Derivatives of d-Lysergic Acid and Model Psychoses". In Rupp C (ed.). Mind as a Tissue: Proceedings of the Fifth International Research Conference Held at the Lankenau Hospital, Philadelphia, Pennsylvania. New York: Harper and Row. pp. 134–169. OCLC 442122. Archived from the original on 30 March 2025.
  9. ↑ Abramson HA (March 1965). "Lysergic acid diethyl amide (LSD-25): XXXVII. Antiserotonin action of lysergic acid derivatives in allergy and neuropsychiatry". The Journal of Asthma Research. 2 (3): 257–262. doi:10.3109/02770906509107712. PMID 14285481.
  10. ↑ Konzett H, Cerletti A (1956). "Spezifische Hemmung von 5-Oxytryptamin-Effekten durch Lysergsäurediäthylamid und ähnliche Körper" [Specific inhibition of serotonin effects by lysergic acid diethylamide and similar compounds]. Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie (in German). 228 (1–2). doi:10.1007/BF00259761. ISSN 0028-1298. Retrieved 5 June 2025.
  11. 1 2 3 Nichols DE, Oberlender R, McKenna DJ (1991). "Stereochemical Aspects of Hallucinogenesis". In Watson RR (ed.). Biochemistry and Physiology of Substance Abuse. Vol. 3. Boca Raton, Fla.: CRC Press. pp. 1–39. ISBN 978-0-8493-4463-3. OCLC 26748320. The 1-hydroxymethyl derivative was estimated to be 66% as potent as LSD, and it also serves as a metabolic intermediate in the demethylation of 1-methyl LSD, which itself is about 1/3 as active as LSD.160,193
  12. ↑ Rothlin E (March 1957). "Lysergic acid diethylamide and related substances". Annals of the New York Academy of Sciences. 66 (3): 668–676. Bibcode:1957NYASA..66..668R. doi:10.1111/j.1749-6632.1957.tb40756.x. PMID 13425249.
  13. ↑ Rothlin E (September 1957). "Pharmacology of lysergic acid diethylamide and some of its related compounds". The Journal of Pharmacy and Pharmacology. 9 (9): 569–587. doi:10.1111/j.2042-7158.1957.tb12312.x. PMID 13463749.
  14. ↑ Cerletti A (1959). "Comparison of Abnormal Behavioral States Induced by Psychotropic Drugs in Animals and Man". In Bradley PB, Deniker P, Radouco-Thomas C (eds.). Proceedings of the 1st International Congress of Neuro-Psychopharmacology, Rome, September 1958. Amsterdam: Elsevier. pp. 117–123. Archived from the original on 30 March 2025.
  15. ↑ Kumbar M, Sankar DV (July 1973). "Quantum chemical studies on drug actions. 3. Correlation of hallucinogenic and anti-serotonin activity of lysergic acid derivatives with quantum chemical data". Research Communications in Chemical Pathology and Pharmacology. 6 (1): 65–100. PMID 4734018. Archived from the original on 29 March 2025. Table I: Structure and Several Biological Activities of Lysergates [...]
  16. ↑ Sankar DV, Kumbar M (February 1974). "Quantum chemical studies on drug actions. IV. Correlation of substituent structures and anti-serotonin activity in lysergamide series". Research Communications in Chemical Pathology and Pharmacology. 7 (2): 259–274. PMID 4818373. Archived from the original on 29 March 2025. Table I: Quantum Chemical Data on Lysergamide Derivatives [...]
  17. ↑ Gupta SP, Singh P, Bindal MC (1 December 1983). "QSAR studies on hallucinogens". Chemical Reviews. 83 (6): 633–649. doi:10.1021/cr00058a003. ISSN 0009-2665. TABLE XII. Antiserotonin and Hallucinogenic Activities and Hückel's Total MO Energy of LSD and its Analogues [...]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=OML-632&oldid=1341405525"